公开(公告)号：US08614065B2

公开(公告)日：2013-12-24

申请号：US13315989

申请日：2011-12-09

申请人： Pablo Umaña ,  Ekkehard Mössner

发明人： Pablo Umaña ,  Ekkehard Mössner

IPC分类号： C07K16/28 ,  G01N33/536 ,  G01N33/558 ,  G01N33/53 ,  G01N33/563 ,  G01N33/574 ,  G01N33/566 ,  A61K51/00

CPC分类号： C07K16/2863 ,  A61K38/179 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6817 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2319/00

摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

公开(公告)号：US20130189287A1

公开(公告)日：2013-07-25

申请号：US13725382

申请日：2012-12-21

申请人： Innate Pharma ,  Paul Scherrer Institut

发明人： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Eliane Fischer ,  Laurent Gauthier ,  Francois Romagné ,  Roger Schibli

IPC分类号： C07K19/00 ,  C12P21/00 ,  C12N9/10 ,  C07C323/60 ,  C07C323/12 ,  C07C247/04 ,  C07D225/08 ,  C07C217/08 ,  C07C229/26 ,  C07C233/62 ,  C07D277/06 ,  C07F9/50 ,  C07D257/08 ,  C07C223/02 ,  G01N33/68

CPC分类号： A61K47/6803 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6817 ,  A61K47/6865 ,  A61K47/6871 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/5022 ,  C07K16/00 ,  C07K19/00 ,  C07K2317/40 ,  C12N9/1044 ,  C12P21/005 ,  G01N33/6854

摘要： The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions

摘要翻译： 本申请涉及用于免疫球蛋白功能化的方法，特别是与药物。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法

公开(公告)号：US08444971B2

公开(公告)日：2013-05-21

申请号：US12516397

申请日：2007-11-27

申请人： Jackie Papkoff ,  Gundo Diedrich ,  Shu-Hui Liu ,  Agnes Nowakowski

发明人： Jackie Papkoff ,  Gundo Diedrich ,  Shu-Hui Liu ,  Agnes Nowakowski

IPC分类号： A61K39/395

CPC分类号： C07K16/2827 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6823 ,  A61K47/6849 ,  A61K47/6855 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12N9/96 ,  G01N33/57492 ,  A61K2300/00

摘要： Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.

摘要翻译： 提供了针对由头颈部，卵巢，子宫内膜，肾，胰腺，肺或乳腺癌表达的Ovr110的分离的抗体及其抗原结合片段。 还提供了用于其生产的细胞和方法及其用于杀死表达Ovr110的癌细胞并减轻或治疗哺乳动物中表达Ovr110的癌症的方法。 抗Ovr110抗体在体外和体内与哺乳动物细胞表达的Ovr110结合时调节Ovr110功能或内在化。 还提供了包含抗Ovr110抗体和载体及其制品或试剂盒的组合物。 此外，提供编码抗Ovr110抗体的分离的核酸，含有分离的核酸的表达载体和含有载体的宿主细胞。

公开(公告)号：US20130034492A1

公开(公告)日：2013-02-07

申请号：US13606899

申请日：2012-09-07

申请人： Hans J. Hansen ,  Chien-Hsing Chang ,  David M. Goldenberg

发明人： Hans J. Hansen ,  Chien-Hsing Chang ,  David M. Goldenberg

IPC分类号： A61K39/395 ,  A61P29/00 ,  A61P5/00 ,  A61P31/00 ,  A61K51/00 ,  A61K51/10

CPC分类号： C07K16/3007 ,  A61K39/39558 ,  A61K47/55 ,  A61K47/60 ,  A61K47/6801 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6815 ,  A61K47/6817 ,  A61K47/6819 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6853 ,  A61K49/0058 ,  A61K49/221 ,  A61K51/088 ,  A61K51/1027 ,  A61K51/1093 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/545 ,  C07K14/54 ,  C07K16/2803 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/515 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30 ,  A61K2300/00

摘要： The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.

公开(公告)号：US20120288498A1

公开(公告)日：2012-11-15

申请号：US13490857

申请日：2012-06-07

申请人： Roy Rabindranauth SOOKNANAN ,  Gilles Bernard TREMBLAY ,  Mario FILION

发明人： Roy Rabindranauth SOOKNANAN ,  Gilles Bernard TREMBLAY ,  Mario FILION

IPC分类号： C07K16/18 ,  A61P35/00 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/00 ,  A61K47/6817 ,  A61K47/6869 ,  A61K48/00 ,  C07K14/47 ,  C07K16/3069 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57449

摘要： The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.

摘要翻译： 本发明涉及与正常细胞相比在癌细胞中差异表达的多核苷酸和多肽序列。 本发明更具体地涉及这些序列在癌症的诊断，预后或治疗以及癌细胞的检测中的用途。

公开(公告)号：US08263744B2

公开(公告)日：2012-09-11

申请号：US12596188

申请日：2008-04-18

申请人： Jeannick Cizeau ,  Glen Christopher Macdonald

发明人： Jeannick Cizeau ,  Glen Christopher Macdonald

IPC分类号： C07K16/00 ,  C07K17/00 ,  C07K17/14 ,  C12P21/08 ,  A61K39/395 ,  A61K39/00

CPC分类号： C07K16/30 ,  A61K38/00 ,  A61K47/6817 ,  A61K47/6849 ,  C07K14/415 ,  C07K2317/52 ,  C07K2317/56

摘要： An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the VH region, CH region, CL region, VL region, the furm linker and the bouganm toxin. The optimized VB6-845 displays improved recombinant protein expression over the original in an E. coli expression system.

摘要翻译： 描述了编码免疫偶联物VB6-845的优化的核酸序列。对原始VB6-845的修饰包括编码VH区，CH区，CL区，VL区，furm连接体和bouganm毒素的核酸序列的变化。 优化的VB6-845在大肠杆菌表达系统中显示优于原始的重组蛋白表达。

公开(公告)号：US20120195879A1

公开(公告)日：2012-08-02

申请号：US13258668

申请日：2010-03-19

申请人： Kenneth W. Walker ,  Yue-Sheng Li ,  Thomas C. Boone ,  Frederick W. Jacobsen ,  HoSung Min ,  Jane Talvenheimo ,  Taruna Arora ,  George Doellgast ,  Janet Doellgast

发明人： Kenneth W. Walker ,  Yue-Sheng Li ,  Thomas C. Boone ,  Frederick W. Jacobsen ,  HoSung Min ,  Jane Talvenheimo ,  Taruna Arora ,  George Doellgast ,  Janet Doellgast

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12N15/63 ,  C07K16/00 ,  C12P21/06 ,  C12N5/16

CPC分类号： C07K16/44 ,  A61K39/39591 ,  A61K47/6817 ,  A61K47/6843 ,  C07K14/43504 ,  C07K14/575 ,  C07K14/605 ,  C07K14/66 ,  C07K16/00 ,  C07K16/18 ,  C07K16/248 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/55

摘要： Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.

摘要翻译： 公开了分离的抗原结合蛋白，例如但不限于抗体或抗体片段。 还公开了包含抗原结合蛋白，编码它的分离的核酸，载体，宿主细胞和用于制备它的方法中的杂交瘤的药物组合物和药物。 在一些实施方案中，抗原结合蛋白包含与其结合的1-24个药理活性化学部分，例如药理学活性多肽。

公开(公告)号：US20120122121A1

公开(公告)日：2012-05-17

申请号：US13276012

申请日：2011-10-18

申请人： Chien-Tsun KUAN ,  Darell D. BIGNER ,  Ira H. PASTAN

发明人： Chien-Tsun KUAN ,  Darell D. BIGNER ,  Ira H. PASTAN

IPC分类号： G01N33/574 ,  C07H21/04

CPC分类号： C07K16/28 ,  A61K47/6817 ,  A61K2039/505 ,  C07K16/1214 ,  C07K16/30 ,  C07K2317/565 ,  C12N15/00 ,  G01N33/57484

摘要： The invention provides high affinity antibodies suitable for forming Immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.

摘要翻译： 本发明提供了适合于形成抑制表达人糖蛋白NMB的细胞生长的免疫毒素的高亲和力抗体，包括成胶质细胞瘤多形细胞，间变性星形细胞瘤细胞，间变性少突神经胶质瘤细胞，少突胶质细胞瘤细胞和黑素瘤细胞。

公开(公告)号：US20120114673A1

公开(公告)日：2012-05-10

申请号：US13357913

申请日：2012-01-25

申请人： Mark S. Dennis ,  William Mallet ,  Paul Polakis

发明人： Mark S. Dennis ,  William Mallet ,  Paul Polakis

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/30

CPC分类号： A61K47/6803 ,  A61K31/337 ,  A61K31/4025 ,  A61K31/4196 ,  A61K31/513 ,  A61K31/517 ,  A61K31/519 ,  A61K31/537 ,  A61K31/555 ,  A61K31/7068 ,  A61K31/7072 ,  A61K38/07 ,  A61K38/08 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6835 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/3015 ,  C07K16/303 ,  C07K16/3069 ,  C07K16/3092 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  Y10T428/13

摘要： The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.

摘要翻译： 本发明涉及可用于诊断和治疗哺乳动物肿瘤的物质的抗体药物共轭组合物，以及使用这些物质组合物的方法。

公开(公告)号：US08158670B2

公开(公告)日：2012-04-17

申请号：US11650059

申请日：2007-01-04

申请人： Lawrence L. Kunz ,  Peter G. Anderson

发明人： Lawrence L. Kunz ,  Peter G. Anderson

IPC分类号： A61K31/40 ,  A61K31/35

CPC分类号： A61K31/04 ,  A61K9/0024 ,  A61K31/00 ,  A61K31/131 ,  A61K31/135 ,  A61K31/138 ,  A61K31/165 ,  A61K31/17 ,  A61K31/337 ,  A61K31/352 ,  A61K31/365 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/519 ,  A61K31/551 ,  A61K31/704 ,  A61K47/50 ,  A61K47/51 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6817 ,  A61K47/6831 ,  A61K47/6843 ,  A61K47/6923 ,  A61K47/6927 ,  A61K47/6957 ,  A61L31/148 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/602 ,  A61L2300/604 ,  A61L2300/606 ,  B82Y5/00 ,  G01N2800/323 ,  Y10S977/775 ,  Y10S977/808 ,  Y10S977/905 ,  Y10S977/906 ,  Y10S977/916

摘要： Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

摘要翻译： 提供了用于在哺乳动物宿主中的血管创伤或疾病之后抑制狭窄的方法，包括向宿主施用治疗有效剂量的含有血管平滑肌结合蛋白的治疗性缀合物，其以特定方式与血管平滑的细胞表面相关联 肌肉细胞，与抑制肌肉细胞的细胞活性的治疗剂剂型偶联。 还提供了用于通过抑制平滑肌细胞收缩导致血管腔的扩张和固定的血管平滑肌细胞的治疗剂的直接和/或靶向递送的方法，从而构成生物支架。